


Product Information



Entecavir (hydrate)

Item No. 13831

CAS Registry No.: 209216-23-9
Formal Name: 2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one, monohydrate
Synonyms: BMS 200475, Baraclude, SQ 34,676
MF: $C_{12}H_{15}N_5O_3 \cdot H_2O$
FW: 295.3
Purity: $\geq 95\%$
Stability: ≥ 2 years at -20°C
Supplied as: A crystalline solid
UV/Vis.: λ_{max} : 256, 254 nm



Laboratory Procedures

For long term storage, we suggest that entecavir (hydrate) be stored as supplied at -20°C . It should be stable for at least two years.

Entecavir (hydrate) is supplied as a crystalline solid. A stock solution may be made by dissolving the entecavir (hydrate) in the solvent of choice. Entecavir (hydrate) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of entecavir (hydrate) in these solvents is approximately 0.1, 12 and 14 mg/ml, respectively.

Entecavir (hydrate) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, entecavir (hydrate) should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Entecavir (hydrate) has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Entecavir is a potent deoxyguanosine nucleoside analog with antiviral activity selective for hepadnaviruses ($\text{EC}_{50} = 3.7$ nM against the hepatitis B virus (HBV) in cultured 2.2.15 liver cells).¹ *In vitro*, the active intracellular form of entecavir, entecavir triphosphate, demonstrates a higher binding affinity for HBV DNA polymerase than the natural guanosine triphosphate substrate and effectively inhibits HBV DNA replication at 3 stages in the replication pathway: priming, reverse transcription, and DNA-dependent DNA synthesis.² The potential therapeutic benefits of entecavir have been demonstrated in woodchuck and duck models of HBV.³ Activity was confirmed in phase I/II preclinical studies and entecavir received approval from the U.S. Food and Drug Administration for the treatment of adults with chronic hepatitis B.⁴

References

1. Innaimo, S.F., Seifer, M., Bisacchi, G.S., *et al.* Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. *Antimicrob. Agents Chemother.* **41**(7), 1444-1448 (1997).
2. Seifer, M., Hamatake, R.K., Colonno, R.J., *et al.* *In vitro* inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. *Antimicrob. Agents Chemother.* **42**(12), 3200-3208 (1998).
3. Marion, P.L., Salazar, F.H., Winters, M.A., *et al.* Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. *Antimicrob. Agents Chemother.* **46**(1), 82-88 (2002).
4. Keeffe, E.B. and Marcellin, P. New and emerging treatment of chronic hepatitis B. *Clin. Gastroenterol. Hepatol.* **5**(3), 285-294 (2007).

Related Products

For a list of related products please visit: www.caymanchem.com/catalog/13831

WARNING: THIS PRODUCT IS FOR LABORATORY RESEARCH ONLY: NOT FOR ADMINISTRATION TO HUMANS. NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

MATERIAL SAFETY DATA

This material should be considered hazardous until information to the contrary becomes available. Do not ingest, swallow, or inhale. Do not get in eyes, on skin, or on clothing. Wash thoroughly after handling. This information contains some, but not all, of the information required for the safe and proper use of this material. Before use, the user must review the complete Material Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Cayman Chemical Company makes **no warranty or guarantee** of any kind, whether written or oral, expressed or implied, including without limitation, any warranty of fitness for a particular purpose, suitability and merchantability, which extends beyond the description of the chemicals hereof. Cayman warrants only to the original customer that the material will meet our specifications at the time of delivery.

Cayman will carry out its delivery obligations with due care and skill. Thus, in no event will Cayman have any obligation or liability, whether in tort (including negligence) or in contract, for any direct, indirect, incidental or consequential damages, even if Cayman is informed about their possible existence.

This limitation of liability does not apply in the case of intentional acts or negligence of Cayman, its directors or its employees.

Buyer's exclusive remedy and Cayman's sole liability hereunder shall be limited to a refund of the purchase price, or at Cayman's option, the replacement, at no cost to Buyer, of all material that does not meet our specifications.

Said refund or replacement is conditioned on Buyer giving written notice to Cayman within thirty (30) days after arrival of the material at its destination. Failure of Buyer to give said notice within thirty (30) days shall constitute a waiver by Buyer of all claims hereunder with respect to said material.

For further details, please refer to our Warranty and Limitation of Remedy located on our website and in our catalog.

Copyright Cayman Chemical Company, 02/8/2013

Cayman Chemical

Mailing address

1180 E. Ellsworth Road
Ann Arbor, MI
48108 USA

Phone

(800) 364-9897
(734) 971-3335

Fax

(734) 971-3640

E-Mail

custserv@caymanchem.com

Web

www.caymanchem.com